Categories Earnings, Health Care

Bio-Path Holdings (NASDAQ: BPTH): 2019 Earnings Snapshot

— Bio-Path Holdings Inc. (NASDAQ: BPTH) reported a loss of $3.24 share for the full year 2019, narrower than a loss of $14.38 per share in the previous year.

— Research and development expenses remained flat from the last year at $4.6 million.

Earnings Update by AlphaStreet

— General and administrative expenses were $4.1 million during the year ended December 31, 2019, up 21% from last year, primarily due to increased legal fees and salaries and benefits expense.

— The company is in the process of initiating a phase 1 study of second pipeline candidates in the first half of this year to evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia patients.

— The company is nearing completion of an investigational new drug (IND)-enabling studies of BP1003 for the treatment of solid tumors, including pancreatic cancer, and expects to file an IND application for phase 1 study in 2020.

— Following the successful completion of the safety testing in Stage 2 of phase 2 clinical trial of prexigebersen in acute myeloid leukemia (AML), the company now plans to advance this program to its next stage in the first half of 2020.

— The company filed an IND application for prexigebersen in the treatment of solid tumors including ovarian and endometrial cancer and expects to start that study later this year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Mattel (MAT): A look at the toymaker’s expectations for the year

Shares of Mattel, Inc. (NASDAQ: MAT) were up slightly on Thursday. The stock has gained 20% year-to-date and 19% over the past three months. There is a level of optimism

Earnings Preview: Paychex likely to report higher Q1 revenue and profit

Paychex Inc. (NASDAQ: PAYX), a leading provider of human capital management solutions, is all set to publish operating results for the first three months of fiscal 2024. The company has

DRI Earnings: Key quarterly highlights from Darden Restaurants’ Q1 2024 financial results

Darden Restaurants, Inc. (NYSE: DRI) reported first quarter 2024 earnings results today. Total sales increased 11.6% to $2.73 billion compared to the same period last year. Blended same-restaurant sales were

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top